Refine by
Oncology Immunology Equipment & Supplies
6 equipment items found
by:Orion Biotechnology Canada, Ltd. based inOttawa, SWITZERLAND
Our approach allows us to focus our discovery and development efforts across peptide and protein GPCR subfamilies, generating a diversified pipeline of potential first-in-class/best-in-class antagonist and agonist therapies against high-value GPCR targets in oncology, immunology and other serious diseases. ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
CG347B is a selective HDAC6 inhibitor, also involves in synthesis of other metalloenzyme inhibitors. HDAC6 inhibitors can be used for oncology, immunology, and neurology ...
Manufactured by:Taconic Biosciences, Inc. based inRensselaer, NEW YORK (USA)
The Black 6 Bom inbred model was developed by Little et al. Hall received stock. Jackson Laboratory received stock from Hall in 1948. Zentralinstitut für Versuchsteirzucht, Hannover Germany (Han) received stock in 1971. M&B A/S (now Taconic Europe) received stock at F141 in 1988. The mice were derived by embryo transfer in January 2000. The Taconic US foundation colony was at F156 + 35 ...
Manufactured by:Base4 based inChicago, ILLINOIS (USA)
Leading the RNA ensemble revolution. Exploiting RNA dynamics: RNAs rapidly exchange between a vast array of distinct 3D conformations, each revealing potentially novel binding surfaces. These dynamics are critical to understanding RNA function and fully exploiting its untapped drug potential. Our proprietary platform is built on unparalleled advancements in RNA structural biology that allows for ...
Manufactured by:Taconic Biosciences, Inc. based inRensselaer, NEW YORK (USA)
One of the most used inbred mouse models, the C57BL/6 is used in nearly every research application, and it's commonly used as the genetic background for transgenic mouse models. It is also the preferred model for studying diet-induced obesity and the chronic experimental autoimmune encephalomyelitis model of multiple ...
by:Intellia Therapeutics, Inc. based inCambridge, MASSACHUSETTS (USA)
We plan to initiate patient screening for a first-in-human Phase 1 study of NTLA-5001, a WT1-directed TCR T cell therapy for the treatment of AML, by the end of 2021. Our first ex vivo development candidate seeks to treat acute myeloid leukemia (AML) by engineering autologous T cell receptors (TCR) directed towards the Wilms’ Tumor 1 (WT1) antigen, an over-expressed protein that is often ...